BR112012022214A2 - métodos e composições para tratar doença de degos - Google Patents

métodos e composições para tratar doença de degos

Info

Publication number
BR112012022214A2
BR112012022214A2 BR112012022214A BR112012022214A BR112012022214A2 BR 112012022214 A2 BR112012022214 A2 BR 112012022214A2 BR 112012022214 A BR112012022214 A BR 112012022214A BR 112012022214 A BR112012022214 A BR 112012022214A BR 112012022214 A2 BR112012022214 A2 BR 112012022214A2
Authority
BR
Brazil
Prior art keywords
compositions
degum
disease
treating
methods
Prior art date
Application number
BR112012022214A
Other languages
English (en)
Inventor
Magro Cynthia
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of BR112012022214A2 publication Critical patent/BR112012022214A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

métodos e composições para tratar doença de degos. a presente descrição refere-se, inter alia, as composições contendo um inibido de complemento humano e/ou um inibidor de interferona alfa, e o uso das composições em métodos para tratar ou prevenir doença de degos em um indivíduo. em algumas modalidades, o inibidor é um anticorpo, ou fragmento de ligação de antígeno do mesmo, que liga-se a uma proteína de componente de complemento humano c5 ou a um fragmento biologicamente ativo de c5 tal como c5a tal como c5a ou c5b. em algumas modalidades, o inibidor é um anticorpo, ou um fragmento de ligação de antígeno do mesmo, que liga-se á interfona alfa ou a um receptor de interferona alfa.
BR112012022214A 2010-03-01 2011-03-01 métodos e composições para tratar doença de degos BR112012022214A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30939310P 2010-03-01 2010-03-01
PCT/US2011/026602 WO2011109338A1 (en) 2010-03-01 2011-03-01 Methods and compositions for treating degos' disease

Publications (1)

Publication Number Publication Date
BR112012022214A2 true BR112012022214A2 (pt) 2017-07-04

Family

ID=44542525

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022214A BR112012022214A2 (pt) 2010-03-01 2011-03-01 métodos e composições para tratar doença de degos

Country Status (14)

Country Link
US (2) US8999340B2 (pt)
EP (1) EP2542255B1 (pt)
JP (3) JP5852021B2 (pt)
KR (1) KR20130009784A (pt)
CN (1) CN102985106A (pt)
AU (1) AU2011223866B2 (pt)
BR (1) BR112012022214A2 (pt)
CA (1) CA2791962A1 (pt)
ES (1) ES2615732T3 (pt)
MX (1) MX2012010116A (pt)
NZ (1) NZ602219A (pt)
RU (2) RU2570390C2 (pt)
SG (1) SG183541A1 (pt)
WO (1) WO2011109338A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2698166B1 (en) 2006-10-10 2015-09-30 Regenesance B.V. Complement inhibition for improved nerve regeneration
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
MX2012010116A (es) * 2010-03-01 2013-02-26 Alexion Pharma Inc Metodos y composiciones para el tratamiento de la enfermedad de degos.
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
KR101870915B1 (ko) 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
HUE041996T2 (hu) 2012-02-20 2019-07-29 Swedish Orphan Biovitrum Ab Publ A C5 humán komplementhez kötõdõ polipeptidek
CA2889170C (en) 2012-10-25 2021-09-07 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
WO2014110438A1 (en) * 2013-01-11 2014-07-17 Alexion Pharmaceuticals, Inc. Compounds and methods related to the c5d domain of complement component c5
JP6608702B2 (ja) 2013-01-31 2019-11-20 ソウル大学校産学協力団 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
RS56663B1 (sr) 2013-03-14 2018-03-30 Alnylam Pharmaceuticals Inc Irnk sastavi komponente komplementa c5 i metode za njihovu upotrebu
WO2014160958A1 (en) * 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
WO2015039126A1 (en) 2013-09-16 2015-03-19 Children hospital medical center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
HUE051746T2 (hu) 2013-10-17 2021-03-29 Omeros Corp Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
EP3207058A1 (en) * 2014-10-15 2017-08-23 Alexion Pharmaceuticals, Inc. Methods of culturing a cell
JP6479974B2 (ja) 2014-10-15 2019-03-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド 大規模エクリズマブ産生細胞培養を再現する方法
TW201809008A (zh) 2014-12-19 2018-03-16 日商中外製藥股份有限公司 抗ｃ５抗體及使用方法
JP7005483B2 (ja) 2015-04-06 2022-02-10 バイオベラティブ ユーエスエー インコーポレイテッド ヒト化抗Ｃ１ｓ抗体及びその使用方法
EP3307318A4 (en) 2015-06-09 2019-01-16 Children's Hospital Medical Center DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR
CA2997745A1 (en) 2015-09-14 2017-03-23 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
SG11201610782YA (en) 2015-12-18 2017-07-28 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
IL309975A (en) 2016-06-14 2024-03-01 Regeneron Pharma Antibodies against C5 and their uses
WO2018025982A1 (ja) 2016-08-05 2018-02-08 中外製薬株式会社 Ｉｌ－８関連疾患の治療用又は予防用組成物
WO2019108456A1 (en) * 2017-12-01 2019-06-06 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
CA3083113A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CN103145842A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006344395B2 (en) * 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US20110130544A1 (en) * 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
KR101947093B1 (ko) * 2007-05-21 2019-02-12 제넨테크, 인크. 루푸스를 확인 및 치료하기 위한 방법 및 조성물
WO2009149306A2 (en) 2008-06-04 2009-12-10 Incode Biopharmaceutics, Inc. Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds
CA3035432A1 (en) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
RU2012102021A (ru) 2009-06-23 2013-07-27 Алексион Фармасьютикалз, Инк. Биспецифические антитела, которые связываются с белками комплемента
MX2012010116A (es) * 2010-03-01 2013-02-26 Alexion Pharma Inc Metodos y composiciones para el tratamiento de la enfermedad de degos.

Also Published As

Publication number Publication date
JP2013521294A (ja) 2013-06-10
WO2011109338A1 (en) 2011-09-09
CN102985106A (zh) 2013-03-20
SG183541A1 (en) 2012-10-30
CA2791962A1 (en) 2011-09-09
RU2015145543A (ru) 2019-01-11
MX2012010116A (es) 2013-02-26
EP2542255A4 (en) 2013-07-31
JP5852021B2 (ja) 2016-02-03
EP2542255B1 (en) 2016-11-16
EP2542255A1 (en) 2013-01-09
US8999340B2 (en) 2015-04-07
RU2570390C2 (ru) 2015-12-10
US20150174243A1 (en) 2015-06-25
AU2011223866A1 (en) 2012-09-27
RU2012141556A (ru) 2014-04-10
JP2016026217A (ja) 2016-02-12
US20130064820A1 (en) 2013-03-14
RU2015145543A3 (pt) 2019-01-11
KR20130009784A (ko) 2013-01-23
AU2011223866B2 (en) 2015-05-21
NZ602219A (en) 2014-10-31
ES2615732T3 (es) 2017-06-08
JP2016026216A (ja) 2016-02-12

Similar Documents

Publication Publication Date Title
BR112012022214A2 (pt) métodos e composições para tratar doença de degos
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
UY32341A (es) Proteínas de unión antígeno novedosas
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
BR112014007382A2 (pt) anticorpos anti-erbb3 e seus usos
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
UA109658C2 (xx) Антитіло проти cgrp
BR112012019098B8 (pt) anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
UY33421A (es) Proteinas de union al antígeno humanizados
NZ604510A (en) Dilutable biocidal compositions and methods of use
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]